Probabilistic disease progression modeling to characterize diagnostic uncertainty: Application to staging and prediction in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Disease progression modeling (DPM) of Alzheimer's disease (AD) aims at revealing long term pathological trajectories from short term clinical data. Along with the ability of providing a data‐driven description of the natural evolution of the pathology, DPM has the potential of representing a valuable clinical instrument for automatic diagnosis, by explicitly describing the biomarker transition from normal to pathological stages along the disease time axis. In this work we reformulated DPM within a probabilistic setting to quantify the diagnostic uncertainty of individual disease severity in an hypothetical clinical scenario, with respect to missing measurements, biomarkers, and follow‐up information. We show that the staging provided by the model on 582 amyloid positive testing individuals has high face validity with respect to the clinical diagnosis. Using follow‐up measurements largely reduces the prediction uncertainties, while the transition from normal to pathological stages is mostly associated with the increase of brain hypo‐metabolism, temporal atrophy, and worsening of clinical scores. The proposed formulation of DPM provides a statistical reference for the accurate probabilistic assessment of the pathological stage of de‐novo individuals, and represents a valuable instrument for quantifying the variability and the diagnostic value of biomarkers across disease stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gaussian Processes for Machine Learning
Rasmussen, C. E., & Williams, C. K. I. (2005) · doi:10.7551/mitpress/3206.001.0001 · Cited by 11,705
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 2×
“A) shows a biologically plausible description of the pathological evolution, compatible with previous fi ndings in longitudinal studies in familial AD (Bateman et al., 2012), and with the hypothetical models of AD progression (Jack et al., 2010; Frisoni et al., 2010).”
BackgroundResultClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“A) shows a biologically plausible description of the pathological evolution, compatible with previous fi ndings in longitudinal studies in familial AD (Bateman et al., 2012), and with the hypothetical models of AD progression (Jack et al., 2010; Frisoni et al., 2010).”
ResultForecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113
Self-citationA Review of Feature Reduction Techniques in Neuroimaging
Mwangi, B., Tian, T. S., & Soares, J. C. (2014) · Neuroinformatics · doi:10.1007/s12021-013-9204-3 · Cited by 559
A data-driven model of biomarker changes in sporadic Alzheimer’s disease
Young, A. L., Oxtoby, N. P., Daga, P., Cash, D. M., Fox, N. C., Ourselin, S., Schott, J. M., & Alexander, D. C. (2014) · Brain · doi:10.1093/brain/awu176 · Cited by 308
Self-citationYoung, J., Modat, M., Cardoso, M. J., Mendelson, A., Cash, D., & Ourselin, S. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.05.004 · Cited by 249 · cited 1×
“This problem requires the de fi nition of optimal ways to integrate and jointly analyze the heterogeneous multi-modal information available to clinicians (Young et al., 2013; Mwangi et al., 2014; Lorenzi et al., 2016).”
BackgroundEstimating long‐term multivariate progression from short‐term data
Donohue, M. C., Jacqmin‐Gadda, H., Le Goff, M., Thomas, R. G., Raman, R., Gamst, A. C., Beckett, L. A., Jack, C. R., Weiner, M. W., Dartigues, J., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.003 · Cited by 197 · cited 6×
“Finally, when applying (Donohue et al., 2014) to the training data we measured a strong agreement between the resulting progression and the one obtained with our method, resulting in a correlation between the corresponding individual time-shifts of 0.94 ( p < 1e-6) (Supplementary Material Appendix…”
BackgroundMethodInfluentialGordon, B. A., Blazey, T., Su, Y., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Benzinger, T. L. S. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2642 · Cited by 105 · cited 2×
“While the absence of pathological amylod levels seems indicative of non-Alzheimer’s pathophysiology [34, 35], there is currently an active debate on the mechanisms of neurodegeneration not related to brain amyloidosis [36].”
Background
Research works printed but not linked: 21
- Guerrero, 2016, Instantiated mixed effects modeling of Alzheimer's disease markers, NeuroImage, 142, 113, 10.1016/j.neuroimage.2016.06.049 · DOI
- Henneman, 2009, Hippocampal atrophy rates in Alzheimer's disease. added value over whole brain volume measures, Neurology, 72, 999, 10.1212/01.wnl.0000344568.09360.31 · DOI · Paper page
- Hill, 2014, Coalition against major diseases/european medicines agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease, Alzheimer’s Dementia, 10, 421, 10.1016/j.jalz.2013.07.003 · DOI · Paper page
- Jack, 2016, Suspected non-Alzheimer disease pathophysiology – concept and controversy, Nat. Rev. Neurol., 12, 117, 10.1038/nrneurol.2015.251 · DOI · Paper page
- Jedynak, 2012, A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease neuroimaging initiative cohort, Neuroimage, 63, 1478, 10.1016/j.neuroimage.2012.07.059 · DOI · Paper page
- Joensuu, 2012, Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts, Lancet Oncol., 13, 265, 10.1016/S1470-2045(11)70299-6 · DOI · Paper page
- Kneip, 1988, Convergence and consistency results for self-modeling nonlinear regression, Ann. Statistics, 82
- Lázaro-Gredilla, 2012, Overlapping mixtures of Gaussian processes for the data association problem, Pattern Recognit., 45, 1386, 10.1016/j.patcog.2011.10.004 · DOI
- Liu, 2010, Estimating replicate time shifts using Gaussian process regression, Bioinformatics, 26, 770, 10.1093/bioinformatics/btq022 · DOI
- Lorenzi, 2010, Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment, Neurobiol. Aging, 31, 1443, 10.1016/j.neurobiolaging.2010.04.036 · DOI · Paper page
- Lorenzi, 2016, Multimodal image analysis in Alzheimer's disease via statistical modelling of non-local intensity correlations, Sci. Rep., 6, 22161, 10.1038/srep22161 · DOI
- McKhann, 1984, Clinical diagnosis of alzheimer's disease report of the nincds-adrda work group* under the auspices of department of health and human services task force on alzheimer's disease, Neurology, 34, 10.1212/WNL.34.7.939 · DOI · Paper page
- Mendelson, 2016, Selection bias in the reported performances of AD classification pipelines, NeuroImage Clin., 14, 400, 10.1016/j.nicl.2016.12.018 · DOI · Paper page
- Mormino, 2016, Heterogeneity in suspected non–Alzheimer disease pathophysiology among clinically normal older individuals, Jama Neurol., 73, 1185, 10.1001/jamaneurol.2016.2237 · DOI · Paper page
- Nickisch, 2008, Approximations for binary Gaussian process classification, J. Mach. Learn. Res., 9, 2035
- Riihimäki, 2010, Gaussian processes with monotonicity information, vol. 9, 645
- Shinkins, 2013, Diagnostic uncertainty: dichotomies are not the answer, Br. J. General Pract., 63, 122, 10.3399/bjgp13X664090 · DOI
- Wolz, 2010, Measurement of hippocampal atrophy using 4D graph-cut segmentation: application to ADNI, NeuroImage, 52, 109, 10.1016/j.neuroimage.2010.04.006 · DOI
- Yang, 2011, Quantifying the pathophysiological timeline of Alzheimer's disease, J. Alzheimer’s Dis., 26, 745, 10.3233/JAD-2011-110551 · DOI · Paper page
- Younes, 2014, Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimer's disease, NeuroImage Clin., 5, 178, 10.1016/j.nicl.2014.04.009 · DOI
- Yu, 2014, Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size, Neurobiol. Aging, 35, 808, 10.1016/j.neurobiolaging.2013.09.039 · DOI · Paper page
Cited by
Kamiya, K., Hori, M., & Aoki, S. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108908 · Cited by 321
Martí-Juan, G., Sanroma-Guell, G., & Piella, G. (2020) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2020.105348 · Cited by 85
Marinescu, R. V., Oxtoby, N. P., Young, A. L., Bron, E. E., Toga, A. W., Weiner, M. W., Barkhof, F., Fox, N. C., Eshaghi, A., Toni, T., et al. (2021) · Machine Learning for Biomedical Imaging · doi:10.59275/j.melba.2021-2dcc · Cited by 68
Self-citationTowards cascading genetic risk in Alzheimer’s disease
Altmann, A., Aksman, L. M., Oxtoby, N. P., Young, A. L., ADNI, Weiner, M., Aisen, P., Petersen, R., Weiner, M., Aisen, P., et al. (2024) · Brain · doi:10.1093/brain/awae176 · Cited by 18
Self-citation
Metadata
- Authors
- Lorenzi, M., Filippone, M., Frisoni, G. B., Alexander, D. C., & Ourselin, S.
- Venue
- NeuroImage
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 190
- Pages
- 56-68
- ISSN
- 1053-8119 (ISSN-L)
- OpenAlex
- W2577478840
- Cited by
- 135
- References
- 12
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 369 d)
- Funders
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- IXICO
- Alzheimer's Drug Discovery Foundation
- Alzheimer's Disease Neuroimaging Initiative
- Eli Lilly and Company
- BioClinica
- Genentech
- Fujirebio Europe
- AbbVie
- Horizon 2020 (666992)
- Alzheimer's Association
- GE Healthcare
- H. Lundbeck A/S
- National Institutes of Health (U01 AG024904)
- Janssen Research and Development
- AXA Research Fund
- U.S. Department of Defense (W81XWH-12-2-0012)
- Biogen
- Eisai
- National Institute on Aging
- University of Southern California
- National Institute of Biomedical Imaging and Bioengineering
- University of California, San Diego
- Johnson and Johnson
- Northern California Institute for Research and Education
- Merck
- Engineering and Physical Sciences Research Council (EP/J020990/01, EP/M020533/1)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.